PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. Hao Qiukui et al. BMJ (Clinical research ed.) 2022 5 e069066

Main|Search|PHGKB